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Background: MIR129-2 has been shown to be a tumor suppressor microRNA hypermethylated in epithelial cancers.
Patients and methods: Epigenetic inactivation of MIR129-2 was studied by methylation-specific PCR (MSP) in 13
cell lines (eight myeloma and five lymphoma), 15 normal controls and 344 primary samples including acute
myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic lymphocytic
leukemia (CLL), non-Hodgkin’s lymphoma (NHL), multiple myeloma (MM) at diagnosis, MM at relapse/progression,
and monoclonal gammopathy of undetermined significance (MGUS). Expression of MIR129 and its target, SOX4, in
cell lines was measured before and after hypomethylating treatment and MIR129 overexpression. MIR129 expression
was correlated with MIR129-2 methylation status in primary lymphoma samples. Tumor suppressor function of
MIR129 was demonstrated by MTT and trypan blue exclusion assay after MIR129 overexpression.
Results: The sensitivity of the methylated-MSP was one in 103. Different MSP statuses, including complete
methylation, partial methylation, and complete unmethylation, were verified by quantitative bisulfite
pyrosequencing. All five lymphoma and seven of eight myeloma cell lines showed complete and partial MIR129-2
methylation. In primary samples, MIR129-2 methylation was absent in AML and CML, but detected in 5% ALL, 45.9%
CLL, 49.5% MM at diagnosis, and 59.1% NHL. In CLL, MIR129-2 methylation adversely impacted on survival (p=0.004).
In MM, MIR129-2 methylation increased from 27.5% MGUS to 49.5% MM at diagnosis and 41.5% at relapse/
progression (p=0.023). In NHL, MIR129-2 methylation was associated with MIR124-1 and MIR203 methylation
(p<0.001), and lower MIR129 expression (p=0.009). Hypomethylation treatment of JEKO-1, homozygously methylated
for MIR129-2, led to MIR129-2 demethylation and MIR129 re-expression, with downregulation of SOX4 mRNA.
Moreover, MIR129 overexpression in both mantle cell lines, JEKO-1 and GRANTA-519, inhibited cellular proliferation
and enhanced cell death, with concomitant SOX4 mRNA downregulation.
Conclusions: MIR129-2 is a tumor suppressive microRNA frequently methylated in lymphoid but not myeloid
malignancies, leading to reversible MIR129-2 silencing. In CLL, MIR129-2 methylation was associated with an inferior
survival. In MM, MIR129-2 methylation might be acquired during progression from MGUS to symptomatic MM. In
NHL, MIR129-2 methylation might collaborate with MIR124-1 and MIR203 methylation in lymphomagenesis.
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DNA methylation, which adds a methyl group to the
number 5 carbon of a cytosine ring of a CpG
dinucleotide, is catalyzed by DNA methyltransferase
[1,2]. Cancers are characterized by a global DNA
hypomethylation and locus-specific hypermethyla-
tion of tumor suppressor gene (TSG). Based on a
pathway-specific approach, multiple TSGs in pathways
including cell cycle regulation, Janus kinase/signal
transducer and activator of transcription (JAK/STAT)
signaling, wingless-type MMTV intergration site fam-
ily (WNT) signaling, and death-associated protein
(DAP) kinase-associated intrinsic tumor suppression,
have been shown to be inactivated by gene hy-
permethylation in leukemia, lymphoma and multiple
myeloma (MM) [1,3].
MicroRNAs are short sequences (22–25 nucleotides)
of non-coding RNA molecules that regulate a range
of biological processes by inducing RNA degradation
and/or translation inhibition of targeted mRNAs [4].
Precise microRNA expression is commonly dysregu-
lated in human diseases, including cancers. In car-
cinogenesis, of these aberrantly expressed microRNAs
in malignant cells, those upregulated microRNAs
which lead to targeting of tumor suppressor genes are
known as oncomiRs. On the other hand, those down-
regulated microRNAs which originally may inactivate
oncogenes are known as tumor suppressive micro-
RNAs [5,6]. Recently, DNA methylation has emerged
as an important mechanism in the regulation of
microRNA expression, in particular, hypermethylation
of microRNA gene promoters may lead to inactivation
of tumor suppressive microRNAs in cancers [7].
In human, MIR129 is transcribed from MIR129-1
and MIR129-2 located on chromosome 7q32 and
11p11 respectively. A CpG island is present in the
proximity of MIR129-2 but not MIR129-1 promoter.
Moreover, loss of MIR129 expression by MIR129-2
methylation has been reported in gastric, endometrial,
and colorectal cancers [8-10], leading to upregulation
of oncogenes including cyclin-dependent kinase 6
(CDK6) and sex determining region Y-box 4 (SOX4)
mRNAs, thereby illustrating the tumor suppressive
effect of MIR129 [9-12].
We therefore investigated the role of MIR129-2
methylation and MIR129-mediated tumor suppression
in a range of hematological malignancies including
acute myeloid leukemia (AML), chronic myelogenous
leukemia (CML), acute lymphoblastic leukemia (ALL),
chronic lymphocytic leukemia (CLL), non-Hodgkin's
lymphoma (NHL), and multiple myeloma (MM), to-
gether with monoclonal gammopathy of undetermined
significance (MGUS), the precursor stage of MM, and
MM at relapse/progression.Results
Methylation-specific PCR: MIR129-2 methylation in
controls and cell lines
Direct sequencing analysis of M-MSP products of a
methylated positive control showed expected conversion
of unmethylated cytosine to uracil (turned into thymidine
after PCR) while leaving methylated cytosine unchanged,
which indicated complete bisulfite conversion and MSP
specificity (Figure 1A). Sensitivity of the MIR129-2 M-
MSP was one in 103 (Figure 1B). None of the 15 healthy
donor samples showed aberrant MIR129-2 methylation
(Figure 1C). On the other hand, 7 of 8 MM cell lines
showed partial MIR129-2 methylation (Figure 1D). More-
over, all of the 5 lymphoma cell lines showed complete
MIR129-2 methylation (Figure 1E). Quantitative bisulfite
pyrosequencing confirmed the methylation statuses (MM,
MU, UU) of the cell lines detected by MSP (Additional file
1: Figure S1A and B). Furthermore, of these completely or
partially methylated cell lines, complete methylation of
the MIR129-2 was associated with a trend of lower
MIR129 expression than those with partial methylation
(Additional file 1: Figure S2).
Methylation-specific PCR: MIR129-2 methylation in
primary samples at diagnosis
There was no MIR129-2 methylation detected in any of
the AML and CML patients (Figure 2A). In ALL,
MIR129-2 methylation was detected in only 1 (5%) of 20
patients. In CLL, MIR129-2 methylation occurred in 28
(45.9%) patients (Figure 2A). MIR129-2 methylation was
not correlated with mean or median hemoglobin level,
lymphocyte and platelet counts. Moreover, there was no
correlation between MIR129-2 methylation and age, gen-
der, Rai stage (≥stage 2), or high-risk karyotypic aberra-
tions. In 50 CLL patients with concomitant data on
MIR34A, MIR124-1, MIR196B and MIR203 methylation,
there was no association with MIR129-2 methylation
with methylation of these microRNAs (data not shown).
On the other hand, the median survivals were signifi-
cantly inferior in patients with MIR129-2 methylation
than those without (49 versus 111 months, p=0.004;
Figure 2B).
Amongst NHL samples, MIR129-2 was methylated in
41 (60.3%) cases, including four NK/T-cell lymphoma
(50.0%), 31 B-cell lymphomas (68.9%), and six T-cell
lymphomas (40.0%). Methylation of MIR129-2 was not
correlated with age, gender, extranodal disease or Ann
Arbor staging. On the other hand, MIR129-2 methylation
was associated with methylation of MIR124-1 (N=68;
p<0.001), MIR203 (N=43; p<0.001) but not that of
MIR34A or MIR196B (Figure 3A). Finally, in 25 primary
lymphoma samples (follicular lymphoma, N=12; diffuse
large B-cell lymphoma, N=13) with both DNA and RNA
available, 20 samples displayed methylated MSP signals
Figure 1 Methylation of MIR129-2. (A) Schematic diagram showing the distribution of CpG dinucleotides (solid vertical lines) along precursor
MIR129-2 and its upstream promoter region. Region of MSP amplification was indicated by the text box marked as “MSP”. Sequence analysis of
the MIR129-2 M-MSP product from bisulfite-treated methylated control DNA showed that the cytosine [C] residues of CpG dinucleotides were
methylated and remained unchanged, whereas all the other C residues were unmethylated and were converted to thymidine [T], indicating
complete bisulfite conversion and specificity of MSP. (B) Sensitivity of the methylated-MSP for the MIR129-2. (C) M- & U-MSP of 15 healthy donor
controls showing no MIR129-2 methylation. (D) All myeloma cell lines, except RPMI-8226, were partially methylated, while RPMI-8226 was
completely unmethylated for MIR129-2. (E) All five lymphoma cell lines were completely methylated for MIR129-2.
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were verified by quantitative pyrosequencing in selected
cases (Additional file 1: Figure S3A and B). Importantly,
samples with methylation of MIR129-2 was associated
with a lower level of mature MIR129 expression, and
hence a higher ΔCt (Ct MIR129 - Ct SNORD48) than those
completely unmethylated samples (p=0.009) (Figure 3C).
In MM, MIR129-2 was methylated in 47 patients
(49.5%) at diagnosis and 12 patients (41.4%) at relapse
(p=0.590). Methylation of MIR129-2 was more frequent
in IgD immunoglobulin isotype, occurring in 3 (100%) of
IgD, 34 (59.5%) of IgG, 8 (34.8%) of IgA, and 2 (18.2%)
of light chain but none of non-secretary MM (p=0.013).
However, there was no association of MIR129-2 methy-
lation with gender, ISS, median OS, or methylation of
MIR34A, MIR124-1, MIR196B or MIR203. Interestingly,MIR129-2 methylation was only detected in 11 (27.5%)
patients with MGUS. Therefore, MIR129-2 methylation
was more frequent in MM at diagnosis than patients
with MGUS (p=0.023).
5-azadC treatment and MIR129 overexpression in
lymphoma cell lines
To investigate if the MIR129-2 methylation might lead
to low MIR129 expression, JEKO-1 with homozygously
methylated MIR129-2 was treated with different concen-
trations of 5-azadC for 3 days and tested for MSP and
stem-loop RT-qPCR. On treatment with 5-azadC,
MIR129-2 was demethylated (Figure 4A; Additional file
1: Figure S4), with a corresponding increase in MIR129
expression (Figure 4B) and downregulation of SOX4
mRNA (Figure 4C), which has been shown to be a direct
Figure 2 Methylation of MIR129-2 in primary samples of hematological malignancies. (A) M- & U-MSP analysis of MIR129-2 in primary
samples of AML, CML, ALL, CLL, NHL, myeloma at diagnosis, and MGUS and myeloma at relapse. (B) Kaplan Meier survival function of CLL
patients with and without MIR129-2 methylation.
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fect of MIR129, MIR129 was overexpressed in JEKO-1
cells (Figure 5A). Upregulation of MIR129 led to SOX4
downregulation (p=0.036, Figure 5Aii). Furthermore,
MIR129 expression resulted in reduction of cellular pro-
liferation as measured by MTT assay (p=0.018,
Figure 5Aiii) and an increase of dead cells as measured
by trypan blue exclusion assay (p=0.017, Figure 5Aiv).
The tumor suppressive effect of MIR129 in the inhib-
ition of cell proliferation and enhancement of cell death
was further demonstrated in GRANTA-519 cells, which
is also completely methylated for MIR129-2 (Figure 5B).
Discussion
In this study, we demonstrated that MIR129-2 was hyper-
methylated in NHL and MM cell lines but not in normal
blood or mononuclear cells, illustrating a methylation
pattern similar to other epigenetically silenced tumor
suppressor microRNAs, such as MIR34A, MIR34B/C,
MIR124, and MIR203, in hematological cancers [13-17].This is in contrast to some methylated microRNAs, such
as MIR127 and MIR373, which show a tissue-specific
methylation pattern, with methylation occurring in both
tumor cells and their normal counterparts [18]. Moreover,
methylation leading to reversible gene silencing was illu-
strated here with re-expression of MIR129 upon hypo-
methylation of MIR129-2. Furthermore, overexpression of
MIR129 led to decreased cell proliferation with increased
cell death. These results were consistent with a tumor
suppressor role of MIR129 in lymphoma cells, similar to
its effects on other epithelial cancers [9-11,19]. In particu-
lar, SOX4, a known target of MIR129, facilitates differenti-
ation of lymphocytes, and has been shown upregulated in
various human cancers [20]. Indeed, herein, downregula-
tion of SOX4 was shown associated with upregulation of
MIR129 upon either hypomethylating treatment or over-
expression in GRANTA-519 and JEKO-1 lymphoma cell
lines. Taken together, the findings indicate that hyper-
methylation of MIR129-2 led to reversible inactivation of
tumor suppressive MIR129 in hematological cancers.
Figure 3 Methylation of MIR129-2 and expression of MIR129 in primary lymphoma samples. (A) Correlations of MIR129-2, MIR203 and
MIR124-1 methylation in samples as shown by M-MSP analysis from 8 representative lymphoma samples. (B) M- & U-MSP analysis of MIR129-2
methylation and (C) stem-loop RT-qPCR analysis of MIR129 expression in 25 primary NHL samples with matched DNA and RNA. Box-and-whisker
plot showed the MIR129 expression (ΔCt: Ct MIR129 – Ct SNORD48) in methylated and unmethylated primary NHL samples. The box indicated the
25th and 75th percentile and the whiskers represent the range. The horizontal line indicated the median. P-value was compared by two-sided
Student t-test.
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MIR129-2, there is no deletion of the MIR129-2 locus, i.e.
chromosome 11p11 [21], and hence complete methylation
in these cells suggests biallelic MIR129-2 methylation.
Secondly, we found that MIR129-2 methylation was fre-
quent and appeared to be associated with poor survival in
CLL patients, which warrants future prospective studies
with larger number of patients. In CLL, apart from ZAP-
70 gene hypermethylation being a favourable prognostic
marker, there is little information on the role of DNA
methylation in the pathogenesis and clinical outcome of
the disease [22-26]. Furthermore, understanding of the
prognostic value of microRNA and microRNA methyla-
tion in CLL remains preliminary [14-16,27-29]. Hence,
our observation of MIR129-2 methylation adversely
impacting on survival in CLL is a novel finding. In order
to establish the prognostic significance of MIR129-2
methylation in CLL, a multivariate analysis together with
Rai stage, lymphocyte counts and high-risk karyotype is
required. However, the small number of patients in this
cohort precluded a multivariate analysis.
In NHL, in contrast toMIR34A, MIR124-1, andMIR203,
which were frequently methylated in NK- or B-celllymphoma, MIR129-2 methylation was frequent but com-
parable among B-, T- or NK-cell lymphomas. However, an
interesting observation was that methylation of MIR129-2,
which is localized to chromosome 11p11, was associated
with methylation of MIR124-1 (localized to 8p23) and
MIR203 (localized to 14q32). As MIR124-1 targets CDK6
mRNA and MIR203 targets ABL and CREB mRNAs, the
strong association of methylation of these microRNAs sug-
gested collaboration of silencing of multiple microRNAs
for oncogenesis [14,16]. Moreover, in lymphoma samples,
in which both DNA and RNA were available, significantly
lower expression of MIR129 was demonstrated in primary
lymphoma samples with MIR129-2 methylation than those
without, further testifying the association of microRNA si-
lencing with microRNA hypermethylation.
In MM, MIR129-2 methylation was more frequent in
MM patients at diagnosis or relapse/progression than
patients with MGUS, and hence might be an important
event implicated in transformation of MGUS to symp-
tomatic MM. Despite that these samples were not
CD138-sorted, the mean and median of plasma cell per-
centage of these MGUS samples were 4.78 and 5 re-
spectively, and hence well within the limit of detection
Figure 4 5-azadC treatment induced DNA demethylation and re-expression of MIR129 leading to re-pression of SOX4. (A) M- & U-MSP of
JEKO-1 lymphoma cells upon 5-azadC treatment. (B) RT-qPCR analysis of the mature MIR129 expression upon treatment. (C) RT-qPCR analysis of
the SOX4 expression upon treatment.
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sorted plasma cells would be ideal, and hence the
current finding warrants further studies using CD138-
sorted samples. On the other hand, there was no impact
of MIR129-2 methylation on OS. However, this cohort
of patients was heterogeneously-treated, and hence the
prognostic impact of MIR129-2 methylation remains to
be verified in a cohort of uniformly-treated patients.
Conclusions
In summary, MIR129 is a putative tumor suppressive
microRNA, and methylated in a tumor-specific manner,
leading to reversible microRNA silencing. MIR129-2
methylation was frequent in lymphoid but uncommon
in myeloid neoplasms. In CLL, MIR129-2 methylation
adversely impacted on survival. In NHL, MIR129-2
methylation was associated with methylation of other
tumor suppressor microRNAs. In MM, MIR129-2
methylation was probably associated with progression
from MGUS to symptomatic MM. Therefore, MIR129-2
methylation is important in the pathogenesis, disease
progression and prognostication in lymphoid neo-
plasms. The implication of MIR129-2 methylation with
methylation of other tumor suppressive microRNAs in
lymphomas warrants further study.Methods
Patient samples
Diagnostic bone marrow or tissue samples were obtained
in 20 ALL, 20 AML, 11 CML in chronic phase, 61 CLL,
68 NHL, 40 MGUS, 95 MM at diagnosis, and 29 MM at
relapse/progression. Patient demographics were listed in
Table 1.
Diagnosis of leukemia and lymphoma were made
according to the French-American-British Classification
and WHO Classification of Tumors respectively [30-33].
In the CLL group, median overall survival (OS) was 81
months for the whole group, and 102 months in those
with limited, and 54 months in those with advanced Rai
stage (p=0.009). Median OS of CLL patient with low/
standard-risk and high-risk karyotypes were 111 months
and 21 months (p<0.001).
In the NHL group, of 36 patients with data available at
clinical presentation, 23 had nodal and 13 had extrano-
dal involvement. Correlation between microRNA me-
thylation and expression was studied in 25 primary
lymphoma samples (follicular lymphoma, N=12; diffuse
large B-cell lymphoma, N=13), in which both DNA and
RNA were available.
The diagnosis of MGUS and MM was based on stan-
dard criteria [34]. Complete staging work-up included
bone marrow examination, skeletal survey, serum and
Figure 5 Ectopic re-expression of MIR129 inhibit cell proliferation and elicited cell death in JEKO-1 and GRANTA-519 cells. (A) JEKO-1.
(B) GRANTA-519. (i) RT-qPCR analysis of mature MIR129 after 48hrs of transfection of lymphoma cells. (ii) RT-qPCR analysis of the SOX4 expression
upon MIR129 overexpression. (iii) Cell proliferation of lymphoma cells in response to overexpression of MIR129 measured by MTT assay. (iv)
Percentage of dead cells in response to MIR129 overexpression measured by trypan blue exclusion method. Error bars represent
standard deviation.
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(IgG, IgA, and IgM) levels. In this cohort, the median OS
was 44 months, and projected 10-year OS was 19.9%. The
median OS were 83 months, 60 months and 23 months in
those with ISS I, II and III disease respectively (p<0.001).
Definitions of relapse and disease progression followed
the criteria of European Group for Blood and Marrow
Transplantation Registry [35]. Briefly, “relapse” from
complete remission (CR) was defined as the reappearance
of the same paraprotein detected by serum/urine protein
electrophoresis, appearance of new bone lesion or extra-
medullary plasmacytoma, or unexplained hypercalcaemia.
The definition of “disease progression” from plateau
phase/stable disease was the same as the definition of re-
lapse except that “a >25% increase in paraprotein level”
replaced “reappearance of the same paraprotein”. The
study has been approved by Institutional Review Board of
Queen Mary Hospital, and written informed consent was
obtained from the patient for publication of this report
and any accompanying data or images.
Cell culture
MM cell lines LP-1 & RPMI-8226 were kindly provided
by Dr Robert Orlowski (Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University
of Texas MD Anderson Cancer Center, Houston, TX,
USA) and WL-2 by Prof. Andrew Zannettino (Myeloma
Research Programme, The University of Adelaide,
Australia). NCI-H929 was purchased from American
Type Culture Collection (Manassas, VA, USA). Other
MM (KMS-12-PE, MOLP-8, OPM-2 and U-266) and
lymphoma (SU-DHL-6, SU-DHL-16, GRANTA-519,
MINO & JEKO-1) cell lines were purchased from
Deutsche Sammlung von Mikroorganismen und Zellkul-
turen (DSMZ) (Braunschweig, Germany). Cell cultures
were maintained in RPMI-1640 (IMDM for LP-1), sup-
plemented with 10% (15% for lymphoma cell lines) fetal
bovine serum, 50 U/ml of penicillin and 50 ug/ml
streptomycin in a humidified atmosphere of 5% CO2 at
37°C. All cell culture reagents were purchased from Invi-
trogen (Carlsbad, CA, USA).
DNA and RNA extractions
DNA was extracted from primary samples, 8 MM cell
lines (KMS-12-PE, LP-1, MOLP-8, NCI-H929, OPM-2,
RPMI-8226, U-266 and WL-2) and 5 lymphoma cell
lines (SU-DHL-6, SU-DHL-16, GRANTA-519, MINO
and JEKO-1), using QIAamp DNA Blood Mini (Qiagen,
Table 1 Patient demographics
ALL (N = 20) Gender (M/F) 11/9
Median age (range) 35 (13–62) years
MIC type (C/PB/EPB/T) 6/10/1/3
AML (N = 20) Gender (M/F) 9/11
Median age (range) 41.5 (20–72) years
FAB type (M1/M2/M4/M5) 3/14/2/1
CLL (N = 61) Gender (M/F) 44/17
Median age (range)* 65 (37–91) years
Rai stage (<2/≥2)* 37/20
Median lymphocyte count (range)* 18.5 (10–236) × 109/L
High-risk [del(17p)/trisomy 12]‡ 1/7
Low-risk [del(13)/normal karyotype/ other karyotype abnormalities]‡ 7/16/6
CML (N = 11) Gender (M/F) 7/4
Median age (range) 41 (22–87) years
Chronic phase 11
MM (N = 95) Gender (M/F) 37/58
Median age (range) 62 (29–91) years
Ig type (G/A/D/LC/NS) 57/23/3/11/1
ISS stage (I/II/III)† 16/36/27
NHL (N = 68) Gender (M/F) 38/30
Median age (range) 60.5 (17–92)
Ann Arbor stage (I/II/III/IV)^ 3/4/4/18
Type (ALCL/ AITL/ PTCL,NOS/ NK-T/ FL/ MZL/ MCL/ DLBCL) 2/ 4/ 9/ 8/ 21/ 7/ 2/ 15
Keys: *, from 59 patients with clinical data; ‡, from 37 patients with cytogenetic data; †, from 79 patients with sufficient data; ^, from 29 patients with Ann Arbor
stage data; A, IgA type; AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large-cell lymphoma; C, common ALL; D, IgD type; DLBCL, diffuse large B-cell
lymphoma; EBP, early B precursor; FAB, French-American-British; FL, follicular lymphoma of grade ≤ 2; G, IgG type; ISS, International Staging System for myeloma;
LC, light chain myeloma; MCL, mantle cell lymphoma; MIC, morphologic-immunophentypic-classification; MZL, marginal zone lymphoma; NK-T, NK/T-cell
lymphoma (nasal or extranasal type); NS, non-secretary myeloma; PB, precursor B ALL; PTCL,NOS, peripheral T-cell lymphoma, not otherwise specified; T, precursor
T ALL.
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mirVana™ miRNA Isolation Kit (Ambion Austin, TX,
USA).
Methylation-specific polymerase chain reaction (MSP)
DNA samples were treated to convert unmethylated cyto-
sine to uracil by EpiTect Bisulfite Kit (Qiagen, Hilden,
Germany). Primers and conditions for methylated-MSP
(M-MSP) and unmethylated-MSP (U-MSP) of MIR129-2
were listed in Table 2. Primers and conditions of MSP for
MIR124-1 and MIR203 were previously described [14,16].
Mononuclear cell DNA from 15 healthy donors [8 bone
marrow, 3 peripheral blood, 3 CD19-sorted peripheral
blood, and 1 CD138-sorted bone marrow (AllCells, CA,
USA)] were used as negative control, and an enzymatically
methylated control DNA purchased from CpGenome Uni-
versal Methylated DNA (Chemicon/Millipore, Billerica,
MA, USA) was used as positive control in all the experi-
ments. Amplified products were then visualized by 6%non-denaturing polyacrylamide gel stained by ethidium
bromide.
Sensitivity of the M-MSP
To establish the sensitivity of the MIR129-2 M-MSP,
1 μg of methylated control DNA was 10-fold serially
diluted in buffer, bisulfite-treated and amplified with
MIR129-2 M-MSP primers.
Quantitative bisulfite pyrosequencing
Bisulfite-treated DNA was used as template. Methylation-
unbiased primer set was used to amplify the promoter re-
gion, which overlapped with the amplicon of the MSP.
Forward: 5’-AGA GGG ATA GGA TAG GTA GG-3’; re-
verse: 5’-AAC CCT AAA ACC CAA CAA ACT AAA
TCT-3’; condition: 2 mM/55°C/50X. A stretch DNA with
9–12 adjacent CpG dinucleotides was pyrosequenced by
sequencing primer: 5’-GGT TTG GAG AAATGG A-3’.
Table 2 Primer sequences and reaction conditions
Gene Forward primer (5’ – 3’) Reverse primer (5’ – 3’) Product size (bp) Tm/cycles
(I) Methylation-specific polymerase chain reaction (MSP)
MIR129-2
M-MSP GAGTTGGGGGATCGCGGAC ATATACCGACTTCTTCGATTCGCCG 188 59°C/ 35
U-MSP GAGTTGGGGGATTGTGGAT AATATACCAACTTCTTCAATTCACCA 189 55°C/ 35
(II) Reverse transcription-polymerase chain reaction (RT-PCR)
SOX4 GCTGGAAGCTGCTCAAAGAC ACCGACCTTGTCTCCCTTCT 167 60°C/ 40
GAPDH ACCACAGTCCATGCCATCACT TCCACCACCCTGTTGCTGTA 452 60°C/ 40
Keys: M-MSP, MSP for the methylated allele; Tm, annealing temperature; U-MSP, MSP for the unmethylated allele.
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JEKO-1 was homozygously methylated for MIR129-2.
Cells were seeded in six-well plates at a density of 1x106
cells/ml and cultured with 0.5–1uM of 5-aza-2’-deoxycy-
tidine (5-azadC) (Sigma–Aldrich) for 3 days.
Quantitative real-time reverse transcription–PCR
(RT-qPCR)
Short mature microRNA transcripts were quantified
using stem-loop RT-qPCR which is a sensitive, specific
and widely-used method designed for microRNA studies
[36]. For MIR129, RT was performed using TaqmanW
MicroRNA RT Kit and TaqmanW MicroRNA Assay Kit
(ABI, Foster City, CA, USA), according to the manufac-
turer’s instructions. Total RNA was reverse transcribed
in 1 mmol/l dNTPs, 50 U MultiScribe™ Reverse Tran-
scriptase, 1× RT Buffer, 3·8 U RNase Inhibitor, and 1×
stem-loop RT primer at following thermal cycling condi-
tion: 16°C for 30 min, 42°C for 30 min, and 85°C for
5 min. RT-qPCR of MIR129 was performed using 1·33 μl
of 1:15 diluted RT product in 1× TaqmanW Universal
PCR Master Mix, and 1× TaqmanW Assay at 95°C for
10 min, followed by 40 cycles of 95°C for 15 s and 60°C
for 1 min. SNORD48 was used as reference for data ana-
lysis with the 2-ΔΔCt method [37]. Conventional RT-
qPCR was used for SOX4 transcript, RT was performed
using QuantiTect Reverse Transcription Kit (Qiagen),
according to the manufacturer’s instructions. RT-qPCR
was performed by iQ SYBR Green Supermix (Bio-Rad),
using GAPDH as endogenous control for data analysis
with the 2-ΔΔCt method [37]. Primers for detecting SOX4
and GAPDH were summarized in Table 2.
MIR129 overexpression in JEKO-1 cells
Cells at log phase were transfected with 150nM of either
negative control mimic or MIR129 oligo mimic (Ambion)
at a density of 106 cell/mL using X-tremeGENE siRNA
transfection reagent (Roche), according to the manufac-
turer’s instructions.MTT assay
Cell proliferation was determined by colorimetric quan-
tification of purple formazan formed from the reduction
of yellow tetrazolium MTT (3-(4, 5-dimethylthiazolyl-2)-
2, 5-diphenyltetrazolium bromide) by proliferating cells.
Briefly, cells were seeded in a 96-well microtitre plate at
5 × 105 /well in 100 μl of medium. At the assay time
point, each well was added 10 μl of 5 mg/ml MTT re-
agent (Sigma-Aldrich), followed by 6-hour incubation,
after which 100 μl of DMSO was added. The absorbance
reading at 550 nm with reference to 650 nm was
recorded. Relative abundances of proliferative viable cells
from three independent experiments were calculated.
Trypan blue exclusion assay
Dead cells were visualized by trypan blue staining and
five random microscopic fields were counted for each
sample. Dead cells (%) = (total number of dead cells per
microscopic field/ total number of cells per microscopic
field) X 100. Percentages of dead cells from three inde-
pendent experiments were calculated.
Statistical analysis
Correlation between MIR129-2 methylation with continu-
ous (mean age) and categorical variables (gender, histo-
logical subtypes, lineage [B, T or NK/T] and nodal/
extranodal presentation) were studied in these 68 patients
by Student’s t-test and Chi-square test (or Fisher Exact
test) respectively. Overall survival (OS) was measured
from the date of diagnosis to the date of last follow-‐up or
death. Survival was plotted by the Kaplan-‐Meier method,
and compared by the log-‐rank test. Moreover, in 25 pri-
mary B-cell NHL samples in which both DNA and RNA
were available, the mean expression of MIR129 in methy-
lated and unmethylated lymphoma was compared by the
Student’s t-test. Association between MIR129-2 methyla-
tion and other previously studied tumor suppressive
microRNA methylation, including MIR34A, MIR124-1,
MIR203 and MIR196B [14-16], in MM, NHL and CLL
patients were studied by Χ2 test. The mean results from
Wong et al. Journal of Hematology & Oncology 2013, 6:16 Page 10 of 11
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compared by Student’s t-test. All p-values were 2-sided.
Additional file
Additional file 1: Figure S1. Quantitative bisulfite pyrosequencing of
MIR129-2. Pyrograms showing the methylation intensity on a stretch of 9
neighboring CpG dinucleotides of (A) Positive control with methylated
DNA and normal control, and (B) Cell lines with defined MSP
methylation statuese (MM, MU, and UU). Figure S2. Expression of MIR129
in cell lines completely or partially methylated for MIR129-2. Box-and
-whisker plot showed complete methylation of MIR129-2 was associated
with a lower level of MIR129 expression, and hence a higher ΔCt (Ct
MIR129 - Ct SNORD48) than partial methylation. The box indicated the
25th and 75th percentile and the whiskers represent the range, or the
25th percentile minus 1.5 X interquartile range when skewed datum (*)
exists. The horizontal line indicated the median. Figure S3. Quantitative
bisulfite pyrosequencing of MIR129-2. Pyrograms showing the
methylation intensity on a stretch of 9 neighboring CpG dinucleotides of
(A) methylated primary NHL samples, and (B) unmethylated primary NHL
samples. Figure S4. Quantitative bisulfite pyrosequencing of MIR129-2.
Pyrograms showing the methylation intensity on a stretch of 9
neighboring CpG dinucleotides of JEKO-1 cells before and after 5-azadC
treatment.
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